Nanovibronix (NASDAQ:NAOV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Nanovibronix (NASDAQ:NAOV) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nanovibronix in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Nanovibronix Stock Performance

Shares of NASDAQ:NAOV opened at $4.13 on Friday. The firm has a market capitalization of $4.49 million, a PE ratio of -0.10 and a beta of 2.16. Nanovibronix has a 52-week low of $3.55 and a 52-week high of $162.50. The firm has a fifty day moving average of $5.68 and a 200 day moving average of $8.56.

Nanovibronix (NASDAQ:NAOV) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.91) earnings per share (EPS) for the quarter. The firm had revenue of $0.72 million for the quarter. Nanovibronix had a negative return on equity of 45.24% and a negative net margin of 380.29%.

Nanovibronix Company Profile

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.